Testing of the new Omicron vaccine has begun on a group of 1,420 volunteers from South Africa and the United States. It includes participants aged 18-55 years.
Pfizer/BioNTech announced the start of clinical trials today. Participants will be divided into three groups: those who received two doses of the existing Pfizer/BioNTech vaccine, who received three vaccinations, and who were not vaccinated at all.
Scientists note that the booster doses of currently used vaccines are effective against severe forms of Omicron, but it is necessary to be prepared for any possible outbreaks.